This research question is not within the scope of research that PCORI funds and would be considered non-responsive. PCORI's research awards focus on CER with patient-centered outcomes. Additionally, PCORI does not fund cost-effectiveness studies comparing the costs of drugs and interventions.
Would studies evaluating FDA safety profiles and affordability of orphan drugs be of interest to PCORI?
Have more questions? Submit a request